Incyte questions remains, says Morgan Stanley - Morgan Stanley said questions
remain following Ph. II trial results of Ruxolitinib. The firm said the
overall survival improvement of .47 is solid but the relevance remains
unclear given the per-specified subgroup is not defined, it is not known if
the subgroup is present in other cancers, and the full details of the benefit
are unknown. Shares remain Underweight rated with a $27 price target.